Image Place holder

Jung Choi, MD, PhD

Specialty: Radiology
Program: Diagnostic Imaging and Interventional Radiology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Dr. Choi received his MD and PhD from the New York University School of Medicine. He completed his radiology residency at the UCLA Medical Center and a body radiology fellowship at the Stanford University Medical Center.

Education & Training

Board Certification:

  • Diagnostic Radiology

Fellowship:

  • Stanford University Medical Center - Body Imaging Radiology Fellowship

Residency:

  • UCLA School of Medicine - Radiological Sciences

Medical School:

  • New York University - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Lu H, Parra NA, Qi J, Gage K, Li Q, Fan S, Feuerlein S, Pow-Sang J, Gillies R, Choi JW, Balagurunathan Y. Repeatability of Quantitative Imaging Features in Prostate Magnetic Resonance Imaging. Front Oncol. 2020 May.10:551. Pubmedid: 32457827. Pmcid: PMC7221156.
  • Polk SL, Choi JW, McGettigan MJ, Rose T, Ahmed A, Kim J, Jiang K, Balagurunathan Y, Qi J, Farah PT, Rathi A, Permuth JB, Jeong D. Multiphase computed tomography radiomics of pancreatic intraductal papillary mucinous neoplasms to predict malignancy. World J Gastroenterol. 2020 Jun.26(24):3458-3471. Pubmedid: 32655269. Pmcid: PMC7327792.
  • El-Kenawi A, Gatenbee C, Robertson-Tessi M, Bravo R, Dhillon J, Balagurunathan Y, Berglund A, Vishvakarma N, Ibrahim-Hashim A, Choi J, Luddy K, Gatenby R, Pilon-Thomas S, Anderson A, Ruffell B, Gillies R. Correction: Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer. Brit J Cancer. 2020 Jan.122(7):1118. Pubmedid: 31937927. Pmcid: PMC7109119.
  • El-Kenawi A, Gatenbee C, Robertson-Tessi M, Bravo R, Dhillon J, Balagurunathan Y, Berglund A, Visvakarma N, Ibrahim-Hashim A, Choi J, Luddy K, Gatenby R, Pilon-Thomas S, Anderson A, Ruffell B, Gillies R. Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer. Brit J Cancer. 2019 Oct.121(7):556-566. Pubmedid: 31417189. Pmcid: PMC6889319.
  • Parra NA, Lu H, Choi J, Gage K, Pow-Sang J, Gillies RJ, Balagurunathan Y. Habitats in DCE-MRI to Predict Clinically Significant Prostate Cancers. Tomography. 2019 Mar.5(1):68-76. Pubmedid: 30854444. Pmcid: PMC6403034.
  • Parra NA, Lu H, Li Q, Stoyanova R, Pollack A, Punnen S, Choi J, Abdalah M, Lopez C, Gage K, Park JY, Kosj Y, Pow-Sang JM, Gillies RJ, Balagurunathan Y. Erratum: Predicting clinically significant prostate cancer using DCE-MRI habitat descriptors. Oncotarget. 2019 Mar.10(21):2113. Pubmedid: 31007853. Pmcid: PMC6459347.
  • Permuth JB, Clark Daly A, Jeong D, Choi JW, Cameron ME, Chen DT, Teer JK, Barnett TE, Li J, Powers BD, Kumar NB, George TJ, Ali KN, Huynh T, Vyas S, Gwede CK, Simmons VN, Hodul PJ, Carballido EM, Judge AR, Fleming JB, Merchant N, Trevino JG. Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities. Cancer Med. 2019 Jun.8(6):3314-3324. Pubmedid: 31074202. Pmcid: PMC6558500.
  • Choi JW, Budzevich M, Wang S, Gage K, Estrella V, Gillies RJ. In vivo positron emission tomographic blood pool imaging in an immunodeficient mouse model using 18F-fluorodeoxyglucose labeled human erythrocytes. PLoS One. 2019 Jan.14(1):e0211012. Pubmedid: 30682160. Pmcid: PMC6347438.
  • Li Q, Lu H, Choi J, Gage K, Feuerlein S, Pow-Sang JM, Gillies R, Balagurunathan Y. Radiological semantics discriminate clinically significant grade prostate cancer. Cancer Imaging. 2019 Dec.19(1):81. Pubmedid: 31796094. Pmcid: PMC6889697.
  • Parra AN, Lu H, Li Q, Stoyanova R, Pollack A, Punnen S, Choi J, Abdalah M, Lopez C, Gage K, Park JY, Kosj Y, Pow-Sang JM, Gillies RJ, Balagurunathan Y. Predicting clinically significant prostate cancer using DCE-MRI habitat descriptors. Oncotarget. 2018 Dec.9(98):37125-37136. Pubmedid: 30647849. Pmcid: PMC6324677.
  • Permuth JB, Chen DT, Yoder SJ, Li J, Smith AT, Choi JW, Kim J, Balagurunathan Y, Jiang K, Coppola D, Centeno BA, Klapman J, Hodul P, Karreth FA, Trevino JG, Merchant N, Magliocco A, Malafa MP, Gillies R. Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Sci Rep. 2017 Sep.7(1):10484. Pubmedid: 28874676. Pmcid: PMC5585319.
  • Permuth JB, Choi JW, Chen DT, Jiang K, DeNicola G, Li JN, Coppola D, Centeno BA, Magliocco A, Balagurunathan Y, Merchant N, Trevino JG, Jeong D. A pilot study of radiologic measures of abdominal adiposity: weighty contributors to early pancreatic carcinogenesis worth evaluating?. Cancer Biol Med. 2017 Feb.14(1):66-73. Pubmedid: 28443205. Pmcid: PMC5365183.
  • Jeong D, Choi JW, Jeong K, Sokol L. CT findings associated with blastic plasmacytoid dendritic cell neoplasm: a case report. Acta Radiol Open. 2016 Jul.5(7):2058460116657688. Pubmedid: 27504192. Pmcid: PMC4963986.
  • Permuth JB, Choi J, Balarunathan Y, Kim J, Chen DT, Chen L, Orcutt S, Doepker MP, Gage K, Zhang G, Latifi K, Hoffe S, Jiang K, Coppola D, Centeno BA, Magliocco A, Li Q, Trevino J, Merchant N, Gillies R, Malafa M, On Behalf Of The Florida Pancreas Collaborative . Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms. Oncotarget. 2016 Dec.7(52):85785-85797. Pubmedid: 27589689. Pmcid: PMC5349874.
  • Rose T, Choi J. Intravenous Imaging Contrast Media Complications: The Basics That Every Clinician Needs to Know. Am J Med. 2015 Sep.128(9):943-949. Pubmedid: 25820169.
  • Kuppler K, Jeong D, Choi JW. Non-infectious cholecystopathy secondary to high-dose IL-2 cancer immunotherapy. Acta Radiol Open. 2015 Oct.4(10):2058460115579458. Pubmedid: 26576289. Pmcid: PMC4641551.
  • Jeong D, Malalis C, Arrington JA, Field AS, Choi JW, Kocak M. Mean apparent diffusion coefficient values in defining radiotherapy planning target volumes in glioblastoma. Quant Imaging Med Surg. 2015 Dec.5(6):835-845. Pubmedid: 26807366. Pmcid: PMC4700247.
  • Abrahams D, Jeune-Smith Y, Bode A, Baldwin M, Choi JW. Real-time ultrasound-guided needle injection of the mouse jugular vein. Curr Protoc Mouse Biol. 2014 Sep.4(3):141-150. Pubmedid: 25723964.
  • Nimgaonkar A, Choi JW, Nguyen L, Triadafilopoulos G. Gastrointestinal dysmotility. Digest Dis Sci. 2012 May.57(5):1130-1133. Pubmedid: 22038542.
  • Hasegawa S, Choi JW, Rao J. Single-cell detection of trans-splicing ribozyme in vivo activity. J Am Chem Soc. 2004 Jun.126(23):7158-7159. Pubmedid: 15186136.
  • Choi JW, Pampeno C, Vukmanovic S, Meruelo D. Characterization of the transcriptional expression of Notch-1 signaling pathway members, Deltex and HES-1, in developing mouse thymocytes. Dev Comp Immunol. 2002 Jul.26(6):575-588. Pubmedid: 12031417.
  • Pampeno CL, Vallerie AM, Choi J, Meruelo NC, Meruelo D. Genomic analysis and localization of murine Deltex, a modulator of notch activity, to mouse chromosome 5 and its human homolog to chromosome 12. DNA Cell Biol. 2001 Mar.20(3):141-148. Pubmedid: 11313017.
  • Yu A, Choi J, Ohno K, Levin B, Rom WN, Meruelo D. Specific cell targeting for delivery of toxins into small-cell lung cancer using a streptavidin fusion protein complex. DNA Cell Biol. 2000 Jul.19(7):383-388. Pubmedid: 10945228.
  • Zebala JA, Choi J, Barany F. Characterization of steady state, single-turnover, and binding kinetics of the TaqI restriction endonuclease. J Biol Chem. 1992 Apr.267(12):8097-8105. Pubmedid: 1569066.
  • Zebala JA, Choi J, Trainor GL, Barany F. DNA recognition of base analogue and chemically modified substrates by the TaqI restriction endonuclease. J Biol Chem. 1992 Apr.267(12):8106-8116. Pubmedid: 1569067.

Patient Comments
Overall Satisfaction
0

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments